Vaccitech to Present at the William Blair Biotech Focus Conference 2022
2022年7月8日 - 5:15AM
Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical
company engaged in the discovery and development of novel
immunotherapeutics and vaccines, today announced that the Company’s
Chief Executive Officer, Bill Enright, will participate in a
fireside chat at the William Blair Biotech Focus Conference 2022 in
New York, July 11 to 12. Mr. Enright will also host one on one
meetings with investors at the conference.
The webcast of the event will be available starting at 9 a.m.
EDT on July 11 and can be accessed through
the Events section of the Vaccitech website. Following
the live webcast, a replay will be available at the same
location.
About Vaccitech plcVaccitech (“the Company”) is
a clinical-stage biopharmaceutical company engaged in the discovery
and development primarily of novel immunotherapies for the
treatment of chronic infectious diseases, cancer, autoimmunity and
diseases where the T cell arm of the immune system is believed to
play an important role. The company’s proprietary platforms include
modified simian adenoviral vectors (ChAdOx1 and ChAdOx2), other
viral vectors including the well-validated Modified Vaccinia Ankara
(MVA) and synthetic nano-particle technologies (SNAPvax™ and
Syntholytic™). The combination of different technologies in a mix
and match approach (heterologous prime-boost) consistently
generates significantly higher magnitudes of T cells compared with
other technologies and approaches. The company has a broad pipeline
of both clinical and preclinical stage therapeutic programs to
treat solid tumors, chronic viral infections, as well as a few
prophylactic viral vaccine programs. Vaccitech co-invented a
COVID-19 vaccine with the University of Oxford, now approved for
use in many territories and exclusively licensed worldwide to
AstraZeneca through Oxford University Innovation, or OUI. Vaccitech
is entitled to receive a share of all milestones and royalty income
received by OUI from AstraZeneca.
Vaccitech Media contacts:Katja Stout, Scius
Communications (EU)Direct: +44 (0)
7789435990Email: katja@sciuscommunications.com
Katie Larch / Robert Flamm, Ph.D., Burns McClellan, Inc.
(U.S.)Email: klarch@burnsmc.com / rflamm@burnsmc.com
Georgy Egorov, CFO, VaccitechEmail: IR@vaccitech.co.uk
Vaccitech (NASDAQ:VACC)
過去 株価チャート
から 5 2024 まで 6 2024
Vaccitech (NASDAQ:VACC)
過去 株価チャート
から 6 2023 まで 6 2024